Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy

Summary

The purpose of this study is to evaluate the effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with non-myeloid cancer on non-platinum chemotherapy, and to investigate quality-of-life benefits associated with the use of epoetin alfa. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

Timeline

Start

1996-08

Primary completion

—

Completion

1998-09

Drugs

Indications